Copy to clipboard 
Amplitude Surgical reported FY 3Q21 orthopedic revenue of USD $33.7 million, +3.7% vs. 3Q20. Compared to FY 3Q19, the pre-pandemic period ending in March 2019, sales declined -6.4%.
The company continues dealing with the fallout of COVID’s third wave and resulting surgical restrictions. In the first half of April 2020, Amplitude observed an acceleration of the public health crisis in its key markets of France, Germany and Brazil. The company’s Novastep foot and ankle business posted nearly +31% growth for the quarter, and over 60% growth in the U.S.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 3Q21 | 3Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $27.8 | $27.7 | $0.2 | 0.7% |
| Knees | $16.0 | $16.2 | ($0.2) | (1.5%) |
| Hips | $11.9 | $11.4 | $0.4 | 3.7% |
| Trauma | $4.1 | $3.2 | $1.0 | 30.8% |
| Sports Medicine | $1.0 | $1.0 | $0.0 | 0.2% |
| Orthobiologics | $0.7 | $0.6 | $0.1 | 7.9% |
| Total | $33.7 | $32.5 | $1.2 | 3.7% |
| 9m21 | 9m20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $74.2 | $79.6 | ($5.4) | (6.8%) |
| Knees | $43.0 | $46.8 | ($3.8) | (8.1%) |
| Hips | $31.2 | $32.8 | ($1.6) | (5%) |
| Trauma | $11.6 | $9.0 | $2.6 | 28.4% |
| Sports Medicine | $2.4 | $2.8 | ($0.4) | (13.4%) |
| Orthobiologics | $1.5 | $1.9 | ($0.3) | (18.3%) |
| Total | $89.7 | $93.3 | ($3.6) | (3.8%) |
Geographic Sales
| 3Q21 | 3Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $22.9 | $21.6 | $1.3 | 5.9% |
| International | $10.8 | $10.9 | ($0.1) | (0.8%) |
| Subsidiaries | $8.2 | $7.6 | $0.6 | 8.1% |
| Distributors | $2.5 | $3.2 | ($0.7) | (21.7%) |
| Total | $33.7 | $32.5 | $1.2 | 3.7% |
| 9m21 | 9m20 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $59.0 | $58.7 | $0.3 | 0.6% |
| International | $30.6 | $34.6 | ($3.9) | (11.3%) |
| Subsidiaries | $23.4 | $25.2 | ($1.7) | (6.8%) |
| Distributors | $7.2 | $9.4 | ($2.2) | (23.4%) |
| Total | $89.7 | $93.3 | ($3.6) | (3.8%) |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Amplitude Surgical reported FY 3Q21 orthopedic revenue of USD $33.7 million, +3.7% vs. 3Q20. Compared to FY 3Q19, the pre-pandemic period ending in March 2019, sales declined -6.4%.
The company continues dealing with the fallout of COVID’s third wave and resulting surgical restrictions. In the first half of April 2020, Amplitude observed...
Amplitude Surgical reported FY 3Q21 orthopedic revenue of USD $33.7 million, +3.7% vs. 3Q20. Compared to FY 3Q19, the pre-pandemic period ending in March 2019, sales declined -6.4%.
The company continues dealing with the fallout of COVID’s third wave and resulting surgical restrictions. In the first half of April 2020, Amplitude observed an acceleration of the public health crisis in its key markets of France, Germany and Brazil. The company’s Novastep foot and ankle business posted nearly +31% growth for the quarter, and over 60% growth in the U.S.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 3Q21 | 3Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $27.8 | $27.7 | $0.2 | 0.7% |
| Knees | $16.0 | $16.2 | ($0.2) | (1.5%) |
| Hips | $11.9 | $11.4 | $0.4 | 3.7% |
| Trauma | $4.1 | $3.2 | $1.0 | 30.8% |
| Sports Medicine | $1.0 | $1.0 | $0.0 | 0.2% |
| Orthobiologics | $0.7 | $0.6 | $0.1 | 7.9% |
| Total | $33.7 | $32.5 | $1.2 | 3.7% |
| 9m21 | 9m20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $74.2 | $79.6 | ($5.4) | (6.8%) |
| Knees | $43.0 | $46.8 | ($3.8) | (8.1%) |
| Hips | $31.2 | $32.8 | ($1.6) | (5%) |
| Trauma | $11.6 | $9.0 | $2.6 | 28.4% |
| Sports Medicine | $2.4 | $2.8 | ($0.4) | (13.4%) |
| Orthobiologics | $1.5 | $1.9 | ($0.3) | (18.3%) |
| Total | $89.7 | $93.3 | ($3.6) | (3.8%) |
Geographic Sales
| 3Q21 | 3Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $22.9 | $21.6 | $1.3 | 5.9% |
| International | $10.8 | $10.9 | ($0.1) | (0.8%) |
| Subsidiaries | $8.2 | $7.6 | $0.6 | 8.1% |
| Distributors | $2.5 | $3.2 | ($0.7) | (21.7%) |
| Total | $33.7 | $32.5 | $1.2 | 3.7% |
| 9m21 | 9m20 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $59.0 | $58.7 | $0.3 | 0.6% |
| International | $30.6 | $34.6 | ($3.9) | (11.3%) |
| Subsidiaries | $23.4 | $25.2 | ($1.7) | (6.8%) |
| Distributors | $7.2 | $9.4 | ($2.2) | (23.4%) |
| Total | $89.7 | $93.3 | ($3.6) | (3.8%) |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
